The Prognostic Significance of Complete Response Rates in Patients with Extensive Stage Small Cell Lung Cancer

Sedef, Ali Murat

doi:10.5505/tjo.2018.1829

Cited by 3 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In summary, all included studies were retrospective studies published between 2008 and 2020. The majority of studies were conducted in Asia ( n = 23) [ 17 , 21 , 23 – 25 , 27 – 30 , 32 , 33 , 36 – 38 , 41 – 44 , 46 – 49 ], primarily China, whereas eight studies [ 16 , 22 , 26 , 31 , 34 , 35 , 50 , 51 ] originated from Europe and two from the USA [ 39 , 40 , 45 ]. A total of 7762 patients with SCLC were included with the number of patients included in each study ranging from 46 to 938.…”

Section: Resultsmentioning

confidence: 99%

“…A total of 7762 patients with SCLC were included with the number of patients included in each study ranging from 46 to 938. In more than half of the studies ( n = 19) [ 17 , 21 , 23 – 25 , 27 – 30 , 33 , 36 , 37 , 41 , 42 , 44 , 45 , 48 – 50 ], the included patients were a mixture of patients with limited disease (LD) and patients with extended disease (ED), whereas only patients with LD were included in eight studies [ 16 , 26 , 31 , 34 , 40 , 43 , 46 , 47 ] and only patients with ED were included in five studies [ 32 , 35 , 38 , 39 , 51 ]. For one study, the stage of disease was not described [ 22 ].…”

Section: Resultsmentioning

confidence: 99%

“…For one study, the stage of disease was not described [ 22 ]. The presence of liver metastasis was described in seven studies [ 30 , 32 , 35 , 38 , 45 , 48 , 51 ] and ranged from 16 to 47% of patients with ED. The median/mean age of included patients varied from 56 to 72 years, and 6–50% of the included patients were female.…”

Section: Resultsmentioning

confidence: 99%

“…N = 113 Median: 61 years (35–83) ED 113 (100) Platinum/etoposide: 98 (87) Etoposide: 6 (1) Best supportive care: 9 (1) 21 (19) 113 (100) 72 (64) NLR:3.0 a PLR: 150 a MLR:0.367 a 6 (1–33) 92 (81%) events during follow-up U: NLR: 2.23 (1.42–3.32) PLR: 1.69 (1.08–2.26) MLR: 0.61 (0.40–0.94) M: NLR: 2.26 (1.25–4.10) PLR and MLR: NR NR Low quality Sakin 2019 Turkey [ 34 ] 1997–2017 Retrospective. N = 90 Median: 59 years (42–83) LD: 90 (100) Platinum/etoposide: 90 (100) 18 (20) 86 (96) PS: 0–2: 77 (86) NLR:3.0 a PLR: 150 a MLR:0.367 a NR 53 (59%) events during follow-up U: NLR: 0.98 (0.89–1.08) PLR: 1.0 (0.99–1.00) MLR: 1.19 (0.41–3.43) M: NLR, PLR and MLR: NR Low quality Sedef 2018 [ 35 ] Turkey September 2011–December 2017 Retrospective. N = 117 Median: 61 years (39–83) ED: 117 (100) Platinum/etoposide: 117 (100) 12 (10) NR NR NLR: 3.28 a PLR: 139.8 a 12 (range NR) 95 (81%) events during follow up U: High NLR: 12 months vs low NLR 14 months p = 0.013 High PLR 13 months vs low PLR 13 months p = 0.66 Low quality Shao 2015 China [ 36 ] January 2000–March 2009 Retrospective.…”

Section: Resultsmentioning

confidence: 99%

“…For two studies [ 38 , 48 ], the time of blood sampling was not reported. Based on the quality assessment, included studies were ranked from low to high quality; 21 studies were ranked low quality [ 16 , 21 , 22 , 24 , 26 – 30 , 33 – 35 , 37 , 38 , 41 , 42 , 45 – 47 , 50 , 51 ], ten studies ranked moderate quality [ 17 , 23 , 25 , 31 , 36 , 39 , 40 , 43 , 44 , 48 ], and two studies ranked high quality [ 32 , 49 ].…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis

2021

View full text Add to dashboard Cite

Background Inflammation scores based on general inflammation markers as leucocyte count or C-reactive protein have been evaluated as prognostic markers of inferior survival in several cancers. In small cell lung cancer (SCLC), however, inflammation scores are less studied. In the present study, we set out to perform a systematic review and meta-analysis investigating reported associations between inflammation scores and overall survival (OS) in SCLC. Methods A literature search was performed in PubMed, Embase, Scopus, and Web of Science following the Preferred Reporting Items for Systematic and Meta-Analyses (PRISMA) guidelines. Of the identified publications, only studies in English containing original data evaluating inflammation scores as a prognostic factor in SCLC patients were included. Hazard ratios (HRs) for OS were pooled in a random-effects model. Results In total, 33 articles were included evaluating eight different inflammation scores in 7762 SCLC patients. Seven of the identified scores were based on leucocyte count. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte (PLR) ratio were the most frequently evaluated scores (NLR: n = 23; PLR: n = 22). For NLR, a meta-analysis including 16 studies demonstrated that patients with a high NLR had a significantly shorter OS compared to patients with a low NLR (pooled HR = 1.39 (95% CI, 1.23–1.56)). For PLR, an association with survival could not be confirmed in a meta-analysis performed based on eight studies (pooled HR = 1.20 (95% CI, 0.96–1.51)). Conclusions This review identifies that inflammation scores based on general inflammation markers have some potential as prognostic biomarkers in SCLC. The meta-analyses indicated that NLR is associated with inferior OS, whereas an association between PLR and OS could not be confirmed. Thus, NLR could be a useful biomarker of OS in SCLC patients. Systematic review registration The protocol for the study was submitted to the PROSPERO database (registration number CRD42020188553).

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis

2021

View full text Add to dashboard Cite

show abstract

Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review

Johal¹,

Hettle²,

Carroll³

et al. 2021

J Thorac Dis

View full text Add to dashboard Cite

Background: Small-cell lung cancer (SCLC) accounts for 12-15% of lung cancers and is associated with poor survival outcomes and high symptom burden. This study employed a broad, systematic search strategy and timeframe to identify evidence on real-world treatment patterns and outcomes for SCLC outside the USA, including understanding sub-populations such as extensive-stage (ES) or limited-stage (LS) disease. Methods: Databases (MEDLINE, Embase, and EBM reviews) were searched for journal articles published in the English language between 1 January 2000-1 March 2020 and supplemented by hand searching of conference abstracts and posters presented at conferences between 1 January 2016-1 March 2020 reporting real-world treatment outcomes in patients with SCLC. A targeted clinical guideline review was also completed. Results: One-hundred studies provided quantitative data; 57 were available as full-text articles, whilst the remaining 43 were presented as abstracts or posters. The majority (80 studies, 80%) of included studies reported treatment in the first-line setting, where platinum-based chemotherapy and chemoradiotherapy was the most commonly used treatment strategy, in line with current treatment guidelines in SCLC. Firstline treatments were found to have a high response rate; however, most patients relapsed early. No studies reported treatment or outcomes with immune-oncology therapies. Second-line treatment options were very limited, and primarily consisted of either re-treatment with first-line regimen or topotecan, but the prognosis for these patients remained poor. Outcomes were particularly poor amongst those with ES or relapsed disease vs. LS disease. Conclusions: SCLC treatment patterns and short survival outcomes have remained constant over the previous 20 years. Due to the search timeframe, none of the studies identified reported on the impact of recently approved immune-oncology therapies in SCLC. Further data is needed on the impact of immunotherapies on treatment patterns and real-world outcomes in SCLC.

show abstract

Inflammation Scores as Prognostic Biomarkers in Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Winther‐Larsen

Aggerholm‐Pedersen

Sandfeld-Paulsen

2020

Preprint

View full text Add to dashboard Cite

Background: Inflammation scores based on general inflammation markers as leucocyte count or C-reactive protein have been evaluated as prognostic markers of inferior survival in several cancers. In small cell lung cancer (SCLC), however, inflammation scores are less studied. In the present study, we set out to perform a systematic review and meta-analysis investigating reported associations between inflammation scores and overall survival (OS) in SCLC. Methods: A literature search was performed in PubMed, Embase, Scopus, and Web of Science following the Preferred Reporting Items for Systematic and Meta-Analyses (PRISMA) guidelines. Of the identified publications, only studies in English containing original data evaluating inflammation scores as a prognostic factor in SCLC patients were included. Hazard ratios (HRs) for OS were pooled in a random-effects model. Results: In total, 33 articles were included evaluating eight different inflammation scores in 7762 SCLC patients. Seven of the identified scores were based on leucocyte count. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte (PLR) ratio were the most frequently evaluated scores (NLR: n=23; PLR: n=22). For NLR, a meta-analysis including 16 studies demonstrated that patients with a high NLR had a significantly shorter OS compared to patients with a low NLR (pooled HR=1.39 (95 % CI, 1.23 – 1.56)). For PLR, an association with survival could not be confirmed in a meta-analysis performed based on eight studies (pooled HR=1.20 (95 % CI, 0.96 – 1.51)). Conclusions: This review identifies that inflammation scores based on general inflammation markers have some potential as prognostic biomarkers in SCLC. The meta-analyses indicated that NLR is associated with inferior OS, whereas an association between PLR and OS could not be confirmed. Thus, NLR could be a useful biomarker of OS in SCLC patients. Systematic Review Registrations: The protocol for the study was submitted to the PROSPERO database (registration number CRD42020188553).

show abstract

The Prognostic Significance of Complete Response Rates in Patients with Extensive Stage Small Cell Lung Cancer

Cited by 3 publications

References 6 publications

Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis

Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis

Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review

Inflammation Scores as Prognostic Biomarkers in Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About